Search

Background: Human epidermal growth factor receptor 2 (HER2) is over-expressed in breast, ovarian, gastric, and prostate cancers and is used as a tumor marker in the diagnosis of cancer. Monoclonal antibodies have been used as a diagnostic and therapeutic tool against HER2. Because of the difficulties associated with the stability and complexity of the construct and the high cost of antibody production, we aimed to investigate, cloning, and expression of HER2- binding DARPins genes to identify, HER2-positive tumor markers, we aimed to investigate. Materials and Methods: After synthesis, the DARPins peptide gene was cloned into the M13 vector and sub-cloned into the TOP10 pet28b bacterial vector. After culturing the bacteria on an agarose plate containing antibiotics, the transfected bacteria expressing the DARPins gene were selected. To ensure gene cloning, we used enzymatic digestion and recombinant plasmid delivery for sequencing. Isopropyl β-d-1-thiogalactopyranosideIPTG was used for the induction of recombinant protein expression and the SDS-PAGE method and Western blot for expression confirmation. Results: The polymerase chain reaction (PCR) amplification product of DARPins was analyzed using agarose gel electrophoresis. Plasmid was purified from the positive clone by PCR cloning, sequenced and gene cloning was confirmed. After culturing from competent cells, protein expression was obtained from positive colonies. SDS- PAGE results showed the effect of different conditions including temperature, IPTG concentration, and time on the pET-DARPins expression. Conclusion: We were succeeded to express a new codon-optimized DARPins gene in Escherichia coli and HEK293t system.

Background: The role of attenuation in antioxidant capacity or expansion of pro-oxidant/oxidant is well known for the development of stress oxidative. The aim of this study was to evaluate the plasma antioxidant capacity along with uric acid in patients with diabetic nephropathy (DN+) and without diabetic nephropathy (DN-). Materials and Methods: The research population included 88 patients with DN, 66 patients without DN and 54 healthy people who were matched for age, gender, and body mass index (BMI). In all groups, total antioxidant capacity of plasma by the ferric reducing antioxidant power (FRAP) assay and serum uric acid by commercial kit, respectively. Results: The mean age of patients in DN+, DN- and control groups were 59.3± 9.4, 60 ±11.2, and 54.6±6.9 years, respectively. Plasma antioxidant capacity was higher in patients with DN+, (1589±330&mu mol/l Fe2+) and DN- (1344± 347 &mu mol/l Fe2+) than that in healthy controls (1187±271 &mu mol/l Fe2+ ) (P

Background: The female breast is subjected to a lifetime of hormonal controls, whose effect is evident at the time of menarche and during the menstrual cycle, pregnancy and lactation. Studies have reported multiple risk factors for breast cancer, some of which are a reflection of hormonally mediated events. The steroid receptors are also served as prognostic factors for evaluating status of malignant tumor of the breast. Estrogen receptor (ER) and progesterone receptor (PgR) formation are influenced by Estrogen and progesterone concentration. The aim of this study was to clarify the hormonal milieu of the breast cancer such as Estradiol (E2), Progesterone (Pg), Prolactin (PRL) and their correlation with prognostic factors like ER, PgR. Materials and Methods: In this study we examined fourthy four samples removed from patients with primary breast cancer by radical mastectomy. The specimens include thirty six malignant and eight benign breast tissues. Blood samples were also obtained before surgery. steroid receptors was assayed by the method of single-point dextrane-coated charcoal (DCC), hormones by radioimmunoassay. Results: The results demonstrated that serum prolactin was higher in patients with benign and malignant tumors than that of normal (progesterone1.5 ng/ml and those of